Sankhe, 120 patient curcumin late treatment RCT: 86% lower mortality [p=0.24], 86% lower ventilation [p=0.24], 10% shorter hospitalization [p=0.4], and 32% faster recovery [p=0.001] https://c19p.org/sankhe2
copied to clipboard
A Randomized, Controlled, Blinded, Parallel Group, Clinical Trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India
et al., Complementary Therapies in Medicine, doi:10.1016/j.ctim.2022.102824
RCT with 60 hospitalized patients treated with Ayurcov and 60 control patients in India, showing improved viral clearance and faster symptom resolution in the mild/moderate group, but no significant differences in the severe group. Ayurcov contains curcuma longa, go ark, sphatika (alum), sita (rock candy), godugdham (bos indicus) milk, and goghritam (bos indicus ghee).
|
risk of death, 85.7% lower, RR 0.14, p = 0.24, treatment 0 of 60 (0.0%), control 3 of 60 (5.0%), NNT 20, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
|
risk of mechanical ventilation, 85.7% lower, RR 0.14, p = 0.24, treatment 0 of 60 (0.0%), control 3 of 60 (5.0%), NNT 20, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
|
risk of ICU admission, 66.7% lower, RR 0.33, p = 0.62, treatment 1 of 60 (1.7%), control 3 of 60 (5.0%), NNT 30.
|
|
hospitalization time, 10.0% lower, relative time 0.90, p = 0.40, treatment 45, control 45, moderate group.
|
|
hospitalization time, 16.7% lower, relative time 0.83, p = 0.20, treatment 15, control 15, severe group.
|
|
recovery time, 31.9% lower, relative time 0.68, p < 0.001, treatment 45, control 45, moderate group, fever.
|
|
recovery time, 36.1% lower, relative time 0.64, p < 0.001, treatment 45, control 45, moderate group, dyspnea.
|
|
recovery time, 4.3% lower, relative time 0.96, p = 0.74, treatment 15, control 15, severe group, fever.
|
|
recovery time, 4.8% higher, relative time 1.05, p = 0.10, treatment 15, control 15, severe group, dyspnea.
|
|
relative Ct increase, 44.4% better, RR 0.56, p = 0.003, treatment mean 9.98 (±6.39) n=44, control mean 5.55 (±6.91) n=43, moderate group.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Sankhe et al., 3/25/2022, Single Blind Randomized Controlled Trial, India, South Asia, peer-reviewed, 10 authors, this trial uses multiple treatments in the treatment arm (combined with gomutra, potassium alum, khadisakhar, bos indicus milk, ghee) - results of individual treatments may vary.
Contact:
apsankhe@bhaktivedantahospital.com (corresponding author), nirmal.rns@gmail.com, drvijaykumar@bhaktivedantahospital.com, drsonal.memane@bhaktivedantahospital.com, ganesh@cse.iitb.ac.in, tkundu@phy.iitb.ac.in, mayur.bagul@bhaktivedantahospital.com, ashutoshk@iitb.ac.in, vbansal108@gmail.com, rashmistats@gmail.com.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.